ACCC association of cancer care centers
Join/Renew
Login
Join/Renew
Login
Education & Resources
ACCC eXchange LogInCorporate Member Sponsored ResourcesPresentations & AbstractsACCC Connect eLearning LogIn
Publications
Oncology IssuesPatient Assistance & Reimbursement GuideTrending Now in Cancer CareBusiness Case Studies for Hiring New Staff
Events
2026 ACCC Leadership SummitAnnual Meeting & Cancer Center Business SummitCapitol Hill DayNational Oncology ConferenceOncology Reimbursement MeetingsOncology State Society Meetings
Policy & Advocacy
ACCC 2026 Policy PrioritiesLetters & StatementsAccess, Payment & Reimbursement ReformWhite Bagging & Brown BaggingAdvocacy ResourcesCancer Moonshot
Membership
Join | RenewWho We AreMembership Types & BenefitsCorporate MembersACCC Member Portal FAQMember Directory
Partners
Oncology State SocietiesPartner OrganizationsCME
News
News ReleasesAdvocacy News ReleasesOncology News
About ACCC
Timeline / 50th Anniversary2025 Impact ReportPresident's ThemeACCC Innovator AwardsACCC FellowsBoard of TrusteesACCC Senior Staff
Breast CancerMetastatic Breast Cancer
Gastrointestinal CancerBiliary Tract CancerColorectal CancerGastric CancerLiver Cancer
Genitourinary CancerBladder CancerProstate CancerRenal Cell Carcinoma
Gynecologic CancerOvarian Cancer
Head & Neck Cancer
Hematologic MalignanciesAcute Lymphocytic Leukemia (ALL)Acute Myeloid Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Multiple Myeloma (MM)Myelodysplastic Syndromes (MDS)
Lung CancerNon-Small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)
Sarcoma
Skin CancerMelanomaNon-Melanoma Skin Cancers (NMSC)
Clinical Practice & TreatmentCancer DiagnosticsCare CoordinationEHR Integration for Biomarker TestingQuality Improvement Collaboration: Integration of Precision Medicine in Community OncologyTreatment
Financial NavigationFAN Boot CampFinancial Advocacy Network (FAN) Resource LibraryPatient Assistance & Reimbursement GuidePrior Authorization
Health Equity & Access3, 2, 1, Go! Practical Solutions for Addressing Cancer Care DisparitiesAppalachian Community Cancer AllianceOncology Advanced PractitionersPersonalizing Care for Patients of All BackgroundsSocial Drivers of Health
Patient-Centered CareAddressing Care Disparities for VeteransAdolescent and Young Adult (AYA)Care Action Plans for People with CancerDermatologic ToxicitiesEmpowering CaregiversGeriatric OncologyHealth LiteracyNutritionOncology PharmacyPatient NavigationPsychosocial Care in OncologyShared Decision-MakingSupportive CareSurvivorship Care
Practice Management & OperationsCancer Program FundamentalsLeadership Sustainment and Engagement VideosOncology Practice Transformation and Integration CenterOncology Team Resiliency
ResearchACCC Community Oncology Research Institute (ACORI)
Technology & InnovationTelehealth & Digital Medicine
ACCCBuzz Blog
CANCER BUZZ Podcast
Oncology Issues
Join/Renew
Login
Breast CancerMetastatic Breast Cancer
Gastrointestinal CancerBiliary Tract CancerColorectal CancerGastric CancerLiver Cancer
Genitourinary CancerBladder CancerProstate CancerRenal Cell Carcinoma
Gynecologic CancerOvarian Cancer
Head & Neck Cancer
Hematologic MalignanciesAcute Lymphocytic Leukemia (ALL)Acute Myeloid Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Multiple Myeloma (MM)Myelodysplastic Syndromes (MDS)
Lung CancerNon-Small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)
Sarcoma
Skin CancerMelanomaNon-Melanoma Skin Cancers (NMSC)
Clinical Practice & TreatmentCancer DiagnosticsCare CoordinationEHR Integration for Biomarker TestingQuality Improvement Collaboration: Integration of Precision Medicine in Community OncologyTreatment
Financial NavigationFAN Boot CampFinancial Advocacy Network (FAN) Resource LibraryPatient Assistance & Reimbursement GuidePrior Authorization
Health Equity & Access3, 2, 1, Go! Practical Solutions for Addressing Cancer Care DisparitiesAppalachian Community Cancer AllianceOncology Advanced PractitionersPersonalizing Care for Patients of All BackgroundsSocial Drivers of Health
Patient-Centered CareAddressing Care Disparities for VeteransAdolescent and Young Adult (AYA)Care Action Plans for People with CancerDermatologic ToxicitiesEmpowering CaregiversGeriatric OncologyHealth LiteracyNutritionOncology PharmacyPatient NavigationPsychosocial Care in OncologyShared Decision-MakingSupportive CareSurvivorship Care
Practice Management & OperationsCancer Program FundamentalsLeadership Sustainment and Engagement VideosOncology Practice Transformation and Integration CenterOncology Team Resiliency
ResearchACCC Community Oncology Research Institute (ACORI)
Technology & InnovationTelehealth & Digital Medicine
ACCCBuzz Blog
CANCER BUZZ Podcast
Oncology Issues
    • Education & Resources
    • Publications
    • Events
    • Policy & Advocacy
    • Membership
    • Partners
    • News
    • About ACCC
ACCC association of cancer care centers
1801 Research Boulevard, Suite 400, Rockville, MD 20850
Tel: 301.984.9496 Email Us
Contact UsVolunteers
Advertise
Career Center
Terms and Conditions
Privacy Policy
ACCC Rebranding
Copyright © 2026 Association of Cancer Care Centers. All Rights Reserved.
HomeACCCBuzz Blog

ACCC Members Respond to CoC’s Draft Standards

July 22, 2019
Randall Oyer, MD

ACCC Members Respond to CoC’s Draft Standards

To demonstrate their delivery of comprehensive, high-quality cancer care, many cancer programs across the country seek accreditation from The American College of Surgeons Commission on Cancer (CoC). When a program earns CoC accreditation, it is recognized for its commitment to excellence in multidisciplinary patient-centered care. The requirements to earn and maintain CoC accreditation are detailed in the Commission on Cancer’s Cancer Program Standards.

Multiple developments are driving the rapid pace of change in cancer care. New discoveries about the biology of cancers as well as new drugs, indications, payment models, data collection and reporting requirements, and EHRs are just a few. Demonstrating quality care to all oncology stakeholders is more important than ever.

But reviewing and revising quality standards in this dynamic environment is no easy task.

Consider just the last seven years. In 2012, the CoC Cancer Program Standards were revised and updated. The addition of Chapter 3, “Continuum of Care Services,” introduced three new Standards: 3.1 Patient Navigation Process, 3.2 Psychosocial Distress Screening, and 3.3 Survivorship Care Plan.

In 2016, the CoC released a new edition of the Cancer Program Standards with further revisions.

Late last year, the CoC announced the launch of a project to “review, analyze, and improve the standards.” The goal: “to ensure that the CoC’s standards result in improvement of patient care, are clearly interpretable, and are accurately measuring the quality of a cancer program.”

Then in spring 2019, the CoC released the draft standards for public feedback. These were open for a several-week public comment period that closed on June 3.

It’s no surprise that the CoC’s draft standards fueled a lively discussion ACCC’s members-only online discussion forum. ACCC members brought multidisciplinary perspectives to the proposed changes and encouraged one another to submit feedback to the CoC.

Although the official comment period ended in early June, ACCCBuzz asked to share a few of our members’ views on the likely real-world impact of some of the proposed changes in three areas: Cancer Registry Quality Control, Quality Improvement, and Survivorship Care Plan.

New Draft Standards 5.4, 5.5, 5.6, and 5.7 Dictating and Formatting of Operative Reports

  • The cancer registry quality control standard was due for a change. Including others (CTR, residents, advanced practice nurses, etc.) is a welcome revision. My program is fortunate to have access to a team of specialized CTRs who regularly review our abstracts, so for us this change is good. 
  • While I appreciate the need to harmonize standards across a variety of their accreditations, the time frame the Commission on Cancer has proposed will be a burden to cancer programs. Implementation of the standards on 1/1/20 only allows around three months to mobilize members, form work groups, and change long-standing hospital and physician practices around the dictating and formatting of specific operative reports (proposed standards 5.4, 5.5, 5.6, 5.7). The use of “phase-in dates” for these proposed standards, similar to what was used during the 2012 changes, would ease our burden.

New Draft Standard 7.3 Quality Improvement

  • The Quality Improvement Standard (7.3) appears too narrow and a bit self-serving with the push to use NCDB/CQIP as the driver. The age of the data makes it frequently irrelevant, the cancer program is likely to have more pressing quality improvement needs that would bring value to patients/programs, and if you’re in compliance with most/all of them, it takes your focus away from tangible improvement to simply doing work to meet a standard.

New Draft Standard XX Survivorship Care Plan No Longer Required

  • While I so appreciate the intent to expand the standard to ensure that survivorship is a longitudinal process and not encapsulated with the scope of one document, SCPs are the cornerstone of any good survivorship program, and it seems to me that by completely removing a standard that hundreds of organizations have spent millions of dollars to address over the last seven years is a huge mistake. . . . 
  • My own personal opinion, after spending a lot of effort on improving our SCPs and the process by which we develop and distribute them, is that they are important. However, I think the current standard forces people to comply with a required percentage rather than looking at the value of the SCPs and their survivorship programs in general. I would like to see the college be less prescriptive regarding how we create and implement survivorship programs and encourage more efforts focused on how we improve the care we provide to cancer survivors. 
  • Though I agree that a survivorship care plan is an important document, those of us in smaller community hospitals have struggled tremendously with achieving compliance. In a perfect world, where all oncology care is provided under one roof, and where there is a true survivorship program with nurses dedicated solely to this population, SCPs make sense. However, in the real world, we have very few, if any, employed physicians in smaller facilities. Our oncology physicians are in private practices utilizing a variety of EHRs that don't necessarily talk to one another. Many physicians are reluctant to allow navigators to access their EHR; therefore, we have to rely on the willingness and ability of their staff to provide us with records. Even when we are able to obtain all the records, create a SCP, and deliver copies of the document to the patient and provider(s), we have no way to monitor if, or how, the document was discussed with the patient. To date, I have not heard back from a single patient or practitioner indicating that the SCP was delivered in the manner it was intended. 
  • For five years I have been trying to garner the cooperation of our physician Cancer Committee members, and though they are sympathetic to my dilemma, nothing has really changed. To improve compliance and understanding of what a SCP is, I developed a cover letter for patients and another for PCPs and oncology physicians explaining the purpose of the SCP, and that it is a requirement we need to fulfill in order to keep our CoC accreditation. The letter did not garner so much as a question from patients or practitioners. The standard is not working for us as community hospitals, and it is not working for the patients if the SCP is nothing more than a piece of paper outlining the diagnosis, treatment rendered, and potential long-term toxicities. As the standard reads at this time, navigators can develop and deliver the SCP to patients and practitioners, but then it must be discussed with the patient by a physician or advanced practitioner in a separate appointment set aside just for this purpose. So, even if we as nurse navigators were willing and able to take on this responsibility, the current and proposed revisions to the standard do not allow us to do so without advanced practitioner credentials.

On November 21, the Commission on Cancer Education Summit—2020: A Glimpse into the Future will focus on the update to the Standards. The following day, there will be half-day workshop on the data submission system and reports under the National Cancer Database’s (NCDB) new data platform, also slated for 2020. Learn more and stay tuned for updates.
____________________________________________________
Randall A. Oyer, MD, is ACCC President-Elect and ACCC Liaison to the Commission on Cancer. Dr. Oyer is medical director of the Cancer Institute, medical director of Oncology, chair of Cancer Committee, chair of the Oncology Physicians Advisory Council, and medical director of the Cancer Risk Evaluation (Cancer Genetics) Program at Penn Medicine Lancaster General.

Related Content

Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung CancerACCCBuzz Blog

Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung Cancer

April 24, 2026

Partnering to Deliver Targeted Treatment: Fox Chase Cancer Center and OmniscopeACCCBuzz Blog

Partnering to Deliver Targeted Treatment: Fox Chase Cancer Center and Omniscope

Rachel Radwan

April 22, 2026

Innovation, Policy, and Partnership: Key Takeaways From the Inaugural ACCC Leadership SummitACCCBuzz Blog

Innovation, Policy, and Partnership: Key Takeaways From the Inaugural ACCC Leadership Summit

Gabrielle Stearns

April 20, 2026

Bispecific Antibodies Are Moving Forward; So Are the Implementation QuestionsACCCBuzz Blog

Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions

Rifeta Kajdić Hodžić

April 17, 2026

Highlights From Volume 41, Number 2 Oncology IssuesACCCBuzz Blog

Highlights From Volume 41, Number 2 Oncology Issues

Gabrielle Stearns

April 15, 2026

Developing Clinical Insight, Professional Competencies, and Strategic Awareness: NCCN 2026 Annual ConferenceACCCBuzz Blog

Developing Clinical Insight, Professional Competencies, and Strategic Awareness: NCCN 2026 Annual Conference

Rachel Radwan; Gabrielle Stearns

April 8, 2026

Representing Veterans in Clinical Trials Through Public-Private Partnerships: A Q&A With NAVREFACCCBuzz Blog

Representing Veterans in Clinical Trials Through Public-Private Partnerships: A Q&A With NAVREF

Gabrielle Stearns

March 26, 2026

Confronting a Lethal Cancer: Duke Launches Multidisciplinary Pancreatic Cancer Center for Earlier Detection and Better OutcomesACCCBuzz Blog

Confronting a Lethal Cancer: Duke Launches Multidisciplinary Pancreatic Cancer Center for Earlier Detection and Better Outcomes

Rachel Radwan

March 25, 2026

Upcoming Events

ACCC Oncology Reimbursement Meeting | Charleston
Oncology

ACCC Oncology Reimbursement Meeting | Charleston

In Person Meeting & NetworkingMay 6, 2026 at 8:00 AM EDT560 King Street, Charleston, SC, USAHyatt Place + Hyatt House Charleston - Historic District, Charleston
Register Now!
ACCC Oncology Reimbursement Meeting | St. Louis
Oncology

ACCC Oncology Reimbursement Meeting | St. Louis

In Person Meeting & NetworkingMay 13, 2026 at 8:00 AM CDT1335 South Lindbergh Boulevard, St. Louis, MO, USAHilton St. Louis Frontenac, St. Louis
Register Now!
ACCC 43rd National Oncology Conference
Oncology

ACCC 43rd National Oncology Conference

In Person Conference & ConventionOctober 21, 2026 at 8:00 AM MDT450 Summer St, Boston, MA 02210Omni Boston Hotel at the Seaport, Boston
Register Now!
Precision in Practice: Translating MRD Into Oncology Care
Oncology

Precision in Practice: Translating MRD Into Oncology Care

In Person Conference & ConventionApril 28, 2026 at 5:30 PM EDT1020 South Calhoun Street, Fort Wayne, IN, USAHilton Fort Wayne at the Grand Wayne Center, Fort Wayne
Register Now!
MOS 2026 Spring Conference
Oncology

MOS 2026 Spring Conference

In Person Conference & ConventionApril 28, 2026 at 5:15 PM CDT1111 East Broadway, Columbia, MO, USAThe Broadway Columbia (A DoubleTree by Hilton), Columbia
Register Now!
RIOS 2026 Spring Symposium
Oncology

RIOS 2026 Spring Symposium

In Person Conference & ConventionMay 9, 2026 at 11:00 AM EDT4 Richmond Square, Providence, RI 02906, USAWaterman Grille, Providence
Register Now!
 HSCO 2026 May Dinner Symposium
Oncology

HSCO 2026 May Dinner Symposium

In Person Conference & ConventionMay 13, 2026 at 5:30 PM HST6600 Kalanianaʻole Highway suite 110, Honolulu, HI, USARoy's Restaurants – Hawaii Kai, Honolulu
Register Now!
WSOS 2026 Laramie Meeting
Oncology

WSOS 2026 Laramie Meeting

In Person Conference & ConventionMay 20, 2026 at 5:30 PM MDT222 South 22nd Street, Laramie, WY, USAUniversity of Wyoming – Rochelle Gateway Center, Laramie
Register Now!
WAHO 2026 Welcome Reception
Oncology

WAHO 2026 Welcome Reception

In Person Conference & ConventionMay 30, 2026 at 6:00 PM CDT1060 W Addison St, Chicago, IL, USAWrigley Field , Chicago
Register Now!
IOS 2026 Welcome Reception
Oncology

IOS 2026 Welcome Reception

In Person Conference & ConventionMay 30, 2026 at 6:00 PM CDT1060 West Addison Street, Chicago, IL, USAWrigley Field, Chicago
Register Now!
Advertisement
Advertisement

Trending Now on
ACCCBuzz Blog

Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung Cancer

Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung Cancer

Small Cell SMASHERS was founded in 2023 as a patient-centered advocacy and education community designed to challenge long-standing narratives about small cell lung cancer and restore a sense of voice, connection, and hope for patients and their loved ones.

Partnering to Deliver Targeted Treatment: Fox Chase Cancer Center and Omniscope

Partnering to Deliver Targeted Treatment: Fox Chase Cancer Center and Omniscope

ACCCBuzz spoke with Fox Chase Cancer Center to learn more about its partnership with Omniscope, a leader in advanced molecular profiling technology, in hopes of developing an assay that accurately predicts which patients will respond well to immunotherapy based on the presence of certain T-cell clones.

Innovation, Policy, and Partnership: Key Takeaways From the Inaugural ACCC Leadership Summit

Innovation, Policy, and Partnership: Key Takeaways From the Inaugural ACCC Leadership Summit

On Friday, April 17, ACCC welcomed oncology leaders from around the country to Washington, DC for the inaugural ACCC Leadership Summit, a forum designed for executive-level decision-makers to engage in strategic dialogue, peer-to-peer exchange, and actionable insights at the highest level of oncology leadership.

Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions

Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions

During the HOPA 2026 annual conference, ACCC brought together a small group of oncology pharmacists for a practical, candid conversation about challenges with the implementation of bispecific antibodies that was deeply grounded in real-world experience and what it takes to operationalize care.

View All ACCCBuzz Blogs

Recently Heard on
CANCER BUZZ Podcast

Innovation in Action: Breaking Down the 2025 ACCC Impact Report – [Mini Podcast] Ep. 228

Transforming Palliative Care in Oncology – [Video Podcast] Ep. 227

Streamlining Access to TIL Cell Therapy for Melanoma – [Podcast] Ep. 226

Policy in Practice: Change Hits the Clinic – [Podcast] Ep. 225

View All Podcasts

Latest from Oncology Issues

April 2026
April 2026
February 2026
December 2025
October 2025
August 2025
View All Oncology Issues

Join the Conversation

ACCC eXchange Digital Banner
Login